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The rapid development of safe and effective COVID­19 
vaccines has been an unprecedented scientific achieve­
ment and offers a promise for a healthy post­pandemic 
future. However, inequitable vaccine access has jeopar­
dised that vision, and our global governance institutions 
have failed to anticipate, prevent, or redress this 
inequality. As of March 21, 2021, 78% of 447 million 
deployed doses of COVID­19 vaccines were in only ten 
countries.1,2 Nearly a quarter of the world’s population 
might not have access to these vaccines before 2022.3
Human rights and fair access to COVID-19 vaccines: 
the International AIDS Society–Lancet Commission on Health 
and Human Rights
normal load group, 45 (88·2% [76·1–95·6], p<0·0001) of 
51 participants in the sonelokimab 120 mg augmented 
load group, and 41 (77·4% [63·8–87·7], p<0·0001) of 
53 participants in the secukinumab 300 mg group. 
Compared with the placebo group (0 [0·0%; 95% CI 
0·0–7·0] of 52 participants), a significantly higher 
proportion of participants in the sonelokimab 120 mg 
augmented load group had a PASI 90 response at week 
12 (39 [76·5%; 62·5–87·2] of 51 participants; p<0·0001).
Although not formally powered as a head­to­
head study of sonelokimab versus secukinumab, the 
preliminary findings reported in this Article1 suggest that 
nanobody IL­17 inhibition could match or even surpass 
traditional antibody therapies used in psoriasis. Studies 
have shown that inhibition of IL­17A binding to the IL­17 
receptor A chain is 30­fold higher with sonelokimab 
versus secukinumab.3 Further studies to evaluate the 
comparative advantages of blockade with nanobodies 
versus canonical antibodies in psoriasis and other 
disorders treated with biologics are needed, and the 
potential of this class of molecules to improve current 
treatments for psoriatic arthritis is also anticipated.
Therapeutic blockade of the IL­17 pathway is not 
without risk, and the side­effects of this class of drugs, 
including mucocutaneous fungal infection and possible 
exacerbation of inflammatory bowel disease, were also 
observed in this study.1 A higher incidence of Candida 
infections was observed in patients who received 
sonelokimab compared with those who received placebo. 
Similarly, a higher incidence of mucocutaneous infections 
were reported in patients with psoriasis who were given 
bimekizumab, which targets both human IL­17A and 
IL­17F, than observed in trials of other biologics used to 
treat chronic plaque psoriasis.4 As highlighted by the 
authors,1 the smaller size of the nanobody compared with 
conventional monoclonal antibodies, combined with the 
addition of IL­17F modulation, could impart important 
differences that influence the overall safety and improve 
the efficacy of psoriasis treatment.
This research is noteworthy for a few reasons. First, 
the study represents the first phase 2b assessment of 
nanobody technology in psoriasis and expands the number 
of patients and duration of therapy of sonelokimab in 
those with chronic plaque psoriasis. Second, the results 
add to what is known about the efficacy and safety of IL­17 
blockade when specific receptor profiles are interrupted. 
Finally, this is the first phase 2b study in which two forms 
of IL­17 blockade were investigated.
Nanotechnology in immunotherapeutics continues the 
trajectory of more targeted, efficacious, and commercially 
stable treatment options, building on the knowledge of 
inhibition of the downstream effects of the IL­17 ligand–
IL­17 receptor complex. Concurrent advances in the 
safety of such specific targeting is also imperative and are 
eagerly awaited.
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As members of the newly established International 
AIDS Society–Lancet Commission on Health and Human 
Rights, we are dismayed at how little attention has 
been given to human rights in discussions of access to 
COVID­19 vaccines. This must change. Unless we hold 
to the principle that everyone has equal rights to dignity, 
to health, and to benefit from scientific progress, our 
success against COVID­19 is at risk.
Unlike research efforts to develop COVID­19 vaccines, 
plans for distributing vaccines in low­income and middle­
income countries (LMICs) have been underwhelming.4 
The consequences are serious. SARS­CoV­2, like any 
virus, mutates.5 Incomplete vaccine coverage, alongside 
ongoing community transmission, facilitates emergence 
of SARS­CoV­2 variants, which may lower vaccine 
efficacy, something already seen in South Africa.6 Yet the 
internationally supported COVAX funding mechanism 
provides only 20% coverage of immunisation for LMICs.7 
This coverage is insufficient to reach all who need it or to 
control viral spread. What citizen, health­care provider, 
or public health official of a wealthy nation would 
find 20% vaccine coverage acceptable?
Inequitable access to COVID­19 vaccines and thera­
peutics mirrors wider health and health­care inequities 
and is grounded in broader structural inequalities, putting 
some populations at greater risk than others. In many 
countries, COVID­19 cases and deaths are highest among 
Indigenous populations and racial minorities, the working 
poor, as well as prisoners and detainees.8,9 In some 
regions, such as southeast Asia, migrant workers are not 
prioritised for vaccination despite high risks for COVID­19 
infection due to poor living conditions.10,11 Many millions 
of displaced people are barely considered in COVID­19 
vaccine distribution schemes.12,13 Some, including the 
Rohingya refugees from Myanmar, have been actively 
excluded.14
A human rights approach offers an alternative. The 
right to the highest attainable standard of health was 
first articulated in 1946 in the Constitution of WHO, 
and nearly every country in the world has ratified at 
least one international agreement that imposes specific 
obligations on governments regarding the right to 
health, including obligations related to “The prevention, 
treatment and control of epidemic, endemic, occupa­
tional and other diseases”.15 The International Covenant 
on Economic, Social and Cultural Rights lays out extrater­
ritorial obligations for international assistance and 
cooperation that are widely understood to include 
equitable global vaccine distribution.15
The notion that it is acceptable for the global wealthy to 
be protected from a life­threatening virus while the global 
poor suffer unprotected was challenged decades ago. 
After the development of effective antiviral therapy for 
HIV/AIDS, about 95% of the world’s people living with HIV 
had no access. But by 2000, the obligation to respond was 
uncontested, leading to the establishment of The Global 
Fund to Fight AIDS, Tuberculosis and Malaria and the 
US President’s Emergency Plan for AIDS Relief (PEPFAR), 
increased financing from development partners, and a 
restructuring of global trade and financing structures 
for HIV treatments, driven by grassroots activism, which 
enabled access to affordable therapy worldwide.16
Similarly, the global community understood with 
smallpox eradication in the 1970s that smallpox 
anywhere was smallpox everywhere. A successful small­
pox vaccine effort was achieved, despite the tensions of 
the Cold War, amid multiple wars of decolonisation and 
liberation.17 It was understood, on scientific and social 
justice grounds, that all of humanity would need to be 
protected to eradicate the disease.
As science achieves such remarkable advances as the 
COVID­19 vaccines, it is compellingly clear that we cannot 
exclude our fellow human beings from benefiting from 
this advance. Allowing that kind of injustice is not only 
legally, politically, and morally unacceptable, but it also 
undermines all of our humanity. Inequitable access to 
COVID­19 vaccines is also reckless public health practice.
There have been demands for a people’s COVID­19 
vaccine with expedited vaccine production and equitable 
distribution.18 The governments of South Africa and 
India have asked the World Trade Organization to waive 
some intellectual property rights for medical products 
until widespread vaccination is in place worldwide.19 
UN human rights experts have called on pharmaceutical 
Panel: Framing questions the Commission will interrogate
1 What is the future of the health and human rights 
framework?
2 How can the health and human rights framework be 
revitalised and reinvigorated to achieve healthy 
communities?
3 What domains of the health and human rights framework 
are most relevant for ensuring robust health systems and 
universal access to prevention and care?
Comment
1526 www.thelancet.com   Vol 397   April 24, 2021
companies to “refrain from causing or contributing 
to adverse impacts on the rights to life and health by 
invoking their intellectual property rights and prioritizing 
economic gains”.20 On scientific, humanitarian, and 
human rights grounds, we need a major effort to create a 
comprehensive system for COVID­19 vaccine production, 
funding, allocation, distribution, and deployment, based 
on true global solidarity.21 The potential introduction of 
COVID­19 vaccine passports reinforces the importance of 
equitable vaccine distribution to avoid unfair distribution 
within resource­constrained settings and further under­
mining the development of emerging economies.22 We 
should insist that a substantial proportion of vaccines 
manufactured for the high­income countries be made 
available to LMICs, concentrating on those vaccines 
with the best data on effectiveness for all; this was the 
approach taken with the smallpox vaccine programme 
and could serve as a precedent for use of COVID­19 
vaccines, which must be seen as global public goods.
The Commission had its first meeting in early 2021 
and expects to produce its first full report in 2022. The 
key questions that will inform our work are shown in the 
panel. We are charged with examining how to ensure 
that human rights are at the core of global health efforts, 
enabling them to fulfil the lofty goals outlined in the WHO 
Constitution, in international human rights treaties, and 
in many national constitutions and legal frameworks: 
that the enjoyment of the highest attainable standard 
of health is one of the fundamental rights of every 
human being without distinction and that the health of 
all peoples is fundamental to the attainment of peace 
and security and is dependent on the fullest cooperation 
of individuals and states.23 The Commission’s work will 
seek to strengthen and expand health and human rights 
efforts to include emerging areas that impact the right to 
health, including misinformation, disinformation, social 
media, and the politicisation of health information; the 
climate crisis and the right to a sustainable environment; 
and the social determinants of health arising from 
inequity, social injustice, and conflict and displacement.
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The Eastern Mediterranean region of WHO stretches 
from Morocco in the west to Pakistan in the east. This 
region’s 22 countries and territories contain great 
contrasts. Life expectancy in Kuwait—84 years for 
women, 79 years for men—is 25 years longer than 
in Somalia.1 The region contains among the richest 
countries in the world, measured by income per person 
(Kuwait, Qatar, and United Arab Emirates), and among 
the poorest (Afghanistan, Djibouti, and Yemen).2 Similar 
to other regions, non­communicable diseases are a 
major burden, and ischaemic heart disease is the leading 
cause of premature mortality in the region.3 Unlike other 
regions, deaths related to conflict are increasing in the 
Eastern Mediterranean region. There have been more 
than 100 000 conflict­related deaths per year since 2014 
in this region, and most such deaths in the world occur in 
the Eastern Mediterranean region.4 Linked to conflict is 
massive displacement of people. By 2019, an estimated 
6·7 million people had left Syria and 6·2 million had been 
internally displaced.5 In Yemen and Iraq, the numbers 
of displaced people are in the millions.6,7 Looking more 
generally at migrants, large numbers are received by Iran, 
Jordan, Lebanon, Pakistan, and Saudi Arabia.8
Conflict and COVID­19 both expose and amplify 
existing inequities in society. Inequities in health can 
be linked to poverty and income inequality; inequities 
in social conditions through the life course; gender 
inequities; problems related to extremes of weather, 
made worse by climate change; and land degrada tion 
with impacts on supplies of food and water. Against this 
background, the Commission on Social Determinants 
of Health in the Eastern Mediterranean was charged 
with assembling the evidence on social determinants 
of health and on inequities in health within and 
between countries and to make recommendations. 
The Commission was convened in 2019 by the WHO 
Regional Office for the Eastern Mediterranean in 
collaboration with the Institute of Health Equity at 
University College London and the Alliance for Health 
Policy and Systems Research, Geneva. The Commission’s 
report Build Back Fairer: Achieving Health Equity in 
the Eastern Mediterranean Region was published on 
March 31, 2021.9 The Build Back Fairer title was chosen 
as a deliberate echo of a 2020 report on COVID­19 and 
socioeconomic and health inequalities in England.10 
Emerging from the COVID­19 pandemic, with its large 
impacts on society, is an opportunity to ask how, based 
on the best evidence, societies and health systems can 
be rebuilt in a way that benefits all people. Doing so will 
be a major step to building greater health equity.
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